



PTO/SB/08a/b (08-03)

Approved for use through 07/31/2003. OMB 0351-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

For the Paperwork Reduction Act of 1995, no person is required to respond to a collection of information unless it contains a valid OMB control number.


|                                 |   |    |   |                        |                   |
|---------------------------------|---|----|---|------------------------|-------------------|
| Substitute for form 1449A/B/PTO |   |    |   | Complete if Known      |                   |
|                                 |   |    |   | Application Number     | 10/791,148        |
|                                 |   |    |   | Filing Date            | March 1, 2004     |
|                                 |   |    |   | First Named Inventor   | Amedeo Leonardi   |
|                                 |   |    |   | Art Unit               | 1614              |
|                                 |   |    |   | Examiner Name          | TBA               |
| Sheet                           | 1 | of | 3 | Attorney Docket Number | 04266/100M619-US3 |

| U.S. PATENT DOCUMENTS |                       |  |                                |  |   |
|-----------------------|-----------------------|--|--------------------------------|--|---|
| Examiner Initials*    | Cite No. <sup>1</sup> | Document Number                          | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document | Pages, Columns, Lines, Where<br>Relevant Passages or Relevant<br>Figures Appear |
|                       |                       | Number-Kind Code <sup>2</sup> (if known) |                                |  |   |
| SUS                   | A                     | 6,517,871                                | 02/11/2003                     | Venkatesh et al.                                   |   |
|                       | B                     | 6,395,728                                | 05/28/2002                     | Webb et al.  |   |
|                       | C                     | 6,204,281                                | 03/20/2001                     | Webb et al.  |   |
|                       | D                     | 6,071,939                                | 08/08/2000                     | Gaviragh et al.                                    |   |
|                       | E                     | 2004/0254178                             | 12/16/2004                     | Grigorieff et al.                                  |   |
|                       | F                     | 2004/0002529                             | 01/01/2004                     | Sada et al.  |   |
|                       | G                     | 2003/0181500                             | 09/25/2003                     | Lee et al.   |   |
|                       | H                     | 2003/0175344                             | 09/18/2003                     | Wald et al.  |   |
|                       | I                     | 2003/0008904                             | 01/09/2003                     | Buch, Jan  |   |
|                       | J                     | 2002/0098241                             | 07/25/2002                     | Venkatesh, Gopadi M.                               |   |

| FOREIGN PATENT DOCUMENTS |                       |   |                                |  |   |
|--------------------------|-----------------------|---|--------------------------------|--|---|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document   | Publication Date<br>MM-DD-YYYY | Name of Patentee or<br>Applicant of Cited Document   | Pages, Columns, Lines,<br>Where Relevant Passages<br>or Relevant Figures Appear |
|                          |                       | Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known) |                                |  |   |
| SUS                      | 1                     | WO 03/097045  | 11/27/2003                     | Novartis Pharma GMBH                                 |   |
|                          | 2                     | WO 03/014084  | 02/20/2003                     | Recordati Ireland Limited                            |   |
|                          | 3                     | WO 02/43807   | 08/06/2002                     | Novartis AG  |   |
|                          | 4                     | WO 02/35046   | 05/02/2002                     | EGHOLM, et al.                                       |   |
|                          | 5                     | WO 02/06253   | 01/24/2002                     | Norvartis-Erfindungen<br>Verwaltungsgesellschaft MBH |   |
|                          | 6                     | WO 01/13800   | 03/01/2001                     | Medicure Inc.  |   |
|                          | 7                     | WO 00/27397   | 05/18/2000                     | Gloxa Group Limited, et al.                          |   |
|                          | 8                     | WO 00/27396   | 05/18/2000                     | Gloxa Group Limited, et al.                          |   |
|                          | 9                     | WO 00/02543   | 01/20/2000                     | Norvartis-Erfindungen<br>Verwaltungsgesellschaft MBH |   |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 801.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS |                       |   |  |  |                |
|---------------------------------|-----------------------|---|--|--|----------------|
| Examiner Initials*              | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. |  |  | T <sup>2</sup> |
| SUS                             | 10                    | Aranda, F.J. et al. (2000) "Therapeutic Efficacy and Tolerability of Lercanidipine versus Candesartan, Alone or in Combination, in Mild-Moderate Essential Hypertensives," <i>Journal of Hypertension</i> 18(2): S152 (abstract)                                |  |  |                |
|                                 | 11                    | Epstein, MD, Murray (2001) "Lercanidipine - A Novel Dihydropyridine Calcium-Channel Blocker," <i>Heart Disease</i> 3: 398-407   |  |  |                |

Examiner Signature  Date Considered 2/18/05

Substitute for form 1449A/B/PTO

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

3

| Complete if Known    |                 |
|----------------------|-----------------|
| Application Number   | 10/791,148      |
| Filing Date          | March 1, 2004   |
| First Named Inventor | Amedeo Leonardi |
| Art Unit             | 1614            |
| Examiner Name        | TBA             |

Attorney Docket Number 04266/100M619-US3

|    |  |
|----|--|
| 12 | Gasser et al. (1999) "Lercanidipine, a new third generation Ca-antagonist in the treatment of hypertension", <i>J Clin Basic Cardiol</i> , 2:169-174   |
| 13 | Grandi et al. (2002) "Aldosterone Antagonist Improves Diastolic Function in Essential Hypertension", <i>Hypertension</i> , 40:647-652  |
| 14 | Kurashivili, Ramaz B. et al. "24-Hour Monitoring in Hypertensive Patients with Type II Diabetes Mellitus: Combination Therapy with Lacidipine and Irbesartan (undated abstract)  |
| 15 | Mancia et al. (1998) "Clinical Advantages of Lipophilic Dihydropyridines", <i>Blood Pressure</i> , 7(suppl 2):23-26  |
| 16 | Mancia and Grassi (1994) "Combination treatment of hypertension", <i>High Blood Pressure</i> , 3 (suppl to No. 4): 5-7   |
| 17 | Martell et al. (2003) "Association of Lercanidipine Plus Enalapril to Control Blood Pressure," presented at the American Society of Hypertension, May 14-17, 2003, New York, NY (abstract)   |
| 18 | Martell et al. (2002) "Asociaciones Terapéuticas en El Control de la Presión Arterial," Poster and Abstract presented at the 7 <sup>th</sup> Reunión Nacional Sociedad Española de Hipertensión Liga Española para la Lucha contra la Hipertensión Arterial, <i>Hipertensión</i> 19(2), Abstract 61T                   |
| 19 | Martell et al. (2002) "Asociaciones Farmacológicas en Hipertensos con Factores de Riesgo Cardiovascular," Poster and Abstract presented at the 7 <sup>th</sup> Reunión Nacional Sociedad Española de Hipertensión Liga Española para la Lucha contra la Hipertensión Arterial, <i>Hipertensión</i> 19(2), Abstract 69T |
| 20 | McClellan and Jarvis (2000) "Lercanidipine: A Review of its Use in Hypertension", <i>Drugs</i> , 60:1123-1140  |
| 21 | Messerli, MD, Franz (2002) "Vasodilatory Edema: A Common Side Effect of Antihypertensive Therapy," <i>Current Cardiology Reports</i> 4: 479-482  |
| 22 | Morgan, Trefor et al. (2002) "A Comparison of Candesartan, Felodipine, and Their Combination in the Treatment of Elderly Patients with Systolic Hypertension," <i>American Journal of Hypertension</i> 15(8): 544-549  |
| 23 | Omboni and Zanchetti (1998) "Antihypertensive efficacy of lercanidipine at 2.5, 5 and 10mg in mild to moderate essential hypertensives assessed by clinic and ambulatory blood pressure measurements", <i>J Hypertens</i> , 16:1831-1838   |
| 24 | Ramsay et al. (1998) "Guidelines for management of hypertension: report of the third working party of the British Hypertension Society", <i>J of Human Hypertension</i> , 13:589-592   |
| 25 | Recordati et al. (2000) "Effects of a reversible 'nephrectomy' on renal sympathetic activity and blood pressure in the rat: evidence for an acute angiotensin-mediated hypertension", <i>Journal of Hypertension</i> , 18:1277-1287  |
| 26 | Rengo and Romis (1997) "Activity of Lercanidipine in Double-Blind Comparison with Nifedipine in Combination Treatment of Patients with Resistant Essential Hypertension", <i>J of Cardiovascular Pharmacology</i> , 29(suppl 2):S54-S58  |
| 27 | Ruzicka, MD, Marcel et al. (2002) "Combination therapy as first-line treatment of arterial hypertension," <i>Can. J. Cardiol.</i> 18(12): 1317-1327  |
| 28 | Sarafidis et al. (2004) "The Effect of Telmisartan and Lercanidipine on Blood Pressure and Insulin Resistance in Hypertensive Patients," <i>Review of Clinical Pharmacology and Pharmacokinetics, International Edition</i> 18:60-66   |

Examiner  
SignatureDate  
Considered

7/1/05

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

3

of


3

| Complete If Known      |                   |
|------------------------|-------------------|
| Application Number     | 10/791,148        |
| Filing Date            | March 1, 2004     |
| First Named Inventor   | Amedeo Leonardi   |
| Art Unit               | 1614              |
| Examiner Name          | TBA               |
| Attorney Docket Number | 04266/100M619-US3 |

|    |   |  |
|----|---|--|
| 29 | van Zwieten (2000) "The influence of antihypertensive drug treatment on the prevention and regression of left ventricular hypertrophy", <i>Cardiovascular Research</i> , 45:82-91 |  |
| 30 | Weir AJH (1998) "The Rationale for Combination Versus Single-Entity Therapy in Hypertension", <i>American Journal of Hypertension</i> , 11:163S-169S                              |  |

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\*Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

|                       |   |                    |         |
|-----------------------|---|--------------------|---------|
| Examiner<br>Signature |  | Date<br>Considered | 7/18/05 |
|-----------------------|---|--------------------|---------|